{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["320(3)"],"submitter":["Lamouse-Smith E"],"pubmed_abstract":["The extensive investigation of the human microbiome and the accumulating evidence regarding its critical relationship to human health and disease has advanced recognition of its potential as the next frontier of drug development. The rapid development of technologies, directed at understanding the compositional and functional dynamics of the human microbiome, and the ability to mine for novel therapeutic targets and biomarkers are leading innovative efforts to develop microbe-derived drugs that can prevent and treat autoimmune, metabolic, and infectious diseases. Increasingly, academics, biotechs, investors, and large pharmaceutical companies are partnering to collectively advance various therapeutic modalities ranging from live bacteria to small molecules. We review the leading platforms "],"journal":["American journal of physiology. Gastrointestinal and liver physiology"],"pagination":["G295-G303"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8609565"],"repository":["biostudies-literature"],"pubmed_title":["Designing bugs as drugs: exploiting the gut microbiome."],"pmcid":["PMC8609565"],"pubmed_authors":["Kelly D","Lamouse-Smith E","De Cremoux I"],"additional_accession":[]},"is_claimable":false,"name":"Designing bugs as drugs: exploiting the gut microbiome.","description":"The extensive investigation of the human microbiome and the accumulating evidence regarding its critical relationship to human health and disease has advanced recognition of its potential as the next frontier of drug development. The rapid development of technologies, directed at understanding the compositional and functional dynamics of the human microbiome, and the ability to mine for novel therapeutic targets and biomarkers are leading innovative efforts to develop microbe-derived drugs that can prevent and treat autoimmune, metabolic, and infectious diseases. Increasingly, academics, biotechs, investors, and large pharmaceutical companies are partnering to collectively advance various therapeutic modalities ranging from live bacteria to small molecules. We review the leading platforms ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T07:54:55.698Z","creation":"2024-11-06T18:53:51.224Z"},"accession":"S-EPMC8609565","cross_references":{"pubmed":["33264062"],"doi":["10.1152/ajpgi.00381.2019"]}}